APACMed China launched the DRG-based value assessment project in 2021 to identify key challenges faced by innovative medical technologies in the ongoing DRG reform of China. APACMed China set up a DRG working group to follow up with key policymakers, KoLs and HCPs in China to develop the first industry research report.
The report, in Chinese, provides an overview of the current landscape, its challenges, as well as key recommendations going forward. An abridged English report is also available.
